bmi md semaglutide Wegovy® – A New Treatment for Obesity Patients with Higher Initial BMIs
Description
Results of a reevaluation of cardiovascular outcomes in the RECORD trial
[DOI] [PubMed] [Google Scholar] 218.Burnett, J
While use of the GLP-1 medications has skyrocketed, evidence on their long-term impact is still being assessed
Researchers choosing between GLP-2(Tirz) and GLP-3(Reta) typically make that call based on whether glucagon receptor contribution is a study variable they need or a confound they want to eliminate
It can, indirectly
